Type 2 Diabetes – References

Adrian Soto-Mota

Current: Director of the Metabolic Diseases Research Unit at Mexico’s National Institute of Medical Sciences and Nutrition

Past: National Autonomous University of Mexico; The University of Oxford

Luis Adrian Soto‑Mota is a physician-scientist renowned for his work in human metabolism, data analysis, and evidence-based medicine. Currently, he

Learn more
References

Type 2 Diabetes – References

  1. Araújo, J., Cai, J., & Stevens, J. (2019). Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. Metabolic Syndrome and Related Disorders, 17(1), 46–52. https://doi.org/10.1089/MET.2018.0105/ASSET/IMAGES/LARGE/FIGURE1.JPEG
  2. Athinarayanan, S. J., Adams, R. N., Hallberg, S. J., McKenzie, A. L., Bhanpuri, N. H., Campbell, W. W., Volek, J. S., Phinney, S. D., & McCarter, J. P. (2019). Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: A 2-year nonrandomized clinical trial. Frontiers in Endocrinology, 10(JUN), 450805. https://doi.org/10.3389/FENDO.2019.00348/BIBTEX
  3. Bellido, V., Abreu Padín, C., Catarig, A. M., Clark, A., Barreto Pittol, S., & Delgado, E. (2022). Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. Journal of Clinical Medicine, 11(17), 4938. https://doi.org/10.3390/JCM11174938/S1
  4. Buchanan, L., Calkins, M., Kalayjian, T., Norwitz, N. G., Teicholz, N., Unwin, D., & Soto-Mota, A. (2025). TOWARD, a metabolic health intervention, demonstrates robust 1-year weight loss and cost-savings through deprescription. Frontiers in Nutrition, 12, 1548609. https://doi.org/10.3389/FNUT.2025.1548609
  5. Buenaventura-Collazos, D. C., García-Ramos, A. F., Balcázar-Valencia, C. M., Aguilar-Londoño, C., Coronel-Restrepo, N., Monsalve-Arango, C. Y., Cuesta-Castro, D. P., & Ramírez-Rincón, A. (2024). Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia. Frontiers in Endocrinology, 15, 1372992. https://doi.org/10.3389/FENDO.2024.1372992/BIBTEX
  6. Crimarco, A., Landry, M. J., & Gardner, C. D. (2022). Ultra-processed Foods, Weight Gain, and Co-morbidity Risk. Current Obesity Reports, 11(3), 80–92. https://doi.org/10.1007/S13679-021-00460-Y/TABLES/3
  7. Cushman, C., Evans, G. W., Byington, R. P., Goff, D. C., Grimm, R. H., Cutler, J. A., Simons-Morton, D. G., Basile, J. N., Corson, M. A., Probstfield, J. L., Katz, L., Peterson, K. A., Friedewald, W. T., Buse, J. B., Thomas, J., Gerstein, H. C., & Ismail-Beigi, F. (2010). Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine, 362(17), 1575–1585. https://doi.org/10.1056/NEJMOA1001286
  8. Herzog, K., Berggren, J., Majdoub, M. Al, Arroyo, C. B., Lindqvist, A., Hedenbro, J., Groop, L., Wierup, N., & Spégel, P. (2020). Metabolic Effects of Gastric Bypass Surgery: Is It All About Calories? Diabetes, 69(9), 2027–2035. https://doi.org/10.2337/DB20-0131
  9. Holmes, P., Bell, H. E., Bozkurt, K., Catarig, A. M., Clark, A., Machell, A., & Sathyapalan, T. (2021). Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. Diabetes Therapy, 12(11), 2891–2905. https://doi.org/10.1007/S13300-021-01141-8/TABLES/6
  10. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMOA2206038/SUPPL_FILE/NEJMOA2206038_DATA-SHARING.PDF
  11. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMOA1607141/SUPPL_FILE/NEJMOA1607141_DISCLOSURES.PDF
  12. Mohammedi, K., Belhatem, N., Berentzen, T. L., Catarig, A. M., & Potier, L. (2023). Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study. Diabetes, Obesity and Metabolism, 25(7), 1855–1864. https://doi.org/10.1111/DOM.15045
  13. Mora, S., Dugani, S. B., Moorthy, M. V., Li, C., Demler, O. V., Alsheikh-Ali, A. A., Ridker, P. M., & Glynn, R. J. (2021). Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiology, 6(4), 437–447. https://doi.org/10.1001/JAMACARDIO.2020.7073
  14. Napoli, R., Berra, C., Catarig, A. M., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F. (2023). Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study. Diabetes, Obesity and Metabolism, 25(6), 1658–1667. https://doi.org/10.1111/DOM.15020
  15. Nicholas, A. P., Soto-Mota, A., Lambert, H., & Collins, A. L. (2021). Restricting carbohydrates and calories in the treatment of type 2 diabetes: A systematic review of the effectiveness of “low-carbohydrate” interventions with differing energy levels. In Journal of Nutritional Science (Vol. 10). Cambridge University Press. https://doi.org/10.1017/jns.2021.67
  16. Riddle, M. C., Cefalu, W. T., Evans, P. H., Gerstein, H. C., Nauck, M. A., Oh, W. K., Rothberg, A. E., Le Roux, C. W., Rubino, F., Schauer, P., Taylor, R., & Twenefour, D. (2021). Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care, 44(10), 2438–2444. https://doi.org/10.2337/DCI21-0034
  17. Rodríguez-Gutiérrez, R., & Montori, V. M. (2016). Glycemic control for patients with type 2 diabetes mellitus: Our evolving faith in the face of evidence. Circulation: Cardiovascular Quality and Outcomes, 9(5), 504–512. https://doi.org/10.1161/CIRCOUTCOMES.116.002901/SUPPL_FILE/CIRCCVQO_CIRCCQO-2016-002901_SUPP1.PDF
  18. Saslow, L. R., Jones, L. M., Sen, A., Wolfson, J. A., Diez, H. L., O’Brien, A., Leung, C. W., Bayandorian, H., Daubenmier, J., Missel, A. L., & Richardson, C. (2023). Comparing Very Low-Carbohydrate vs DASH Diets for Overweight or Obese Adults With Hypertension and Prediabetes or Type 2 Diabetes: A Randomized Trial. The Annals of Family Medicine, 21(3), 256–263. https://doi.org/10.1370/AFM.2968
  19. Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019). Understanding the mechanisms of reversal of type 2 diabetes. In The Lancet Diabetes and Endocrinology (Vol. 7, Issue 9, pp. 726–736). https://doi.org/10.1016/S2213-8587(19)30076-2
  20. Unwin, D., Delon, C., Unwin, J., Tobin, S., & Taylor, R. (2023). What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a lower carbohydrate diet with weight loss. BMJ Nutrition, Prevention & Health, 6(1), 544. https://doi.org/10.1136/BMJNPH-2022-000544
  21. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMOA2032183/SUPPL_FILE/NEJMOA2032183_DATA-SHARING.PDF
  22. Wright, D. R., Guo, J., & Hernandez, I. (2023). A Prescription for Achieving Equitable Access to Antiobesity Medications. JAMA Health Forum, 4(4), e230493–e230493. https://doi.org/10.1001/JAMAHEALTHFORUM.2023.0493
  23. Zhou, B., Rayner, A. W., Gregg, E. W., Sheffer, K. E., Carrillo-Larco, R. M., Bennett, J. E., Shaw, J. E., Paciorek, C. J., Singleton, R. K., Barradas Pires, A., Stevens, G. A., Danaei, G., Lhoste, V. P., Phelps, N. H., Heap, R. A., Jain, L., D’Ailhaud De Brisis, Y., Galeazzi, A., Kengne, A. P., … Ezzati, M. (2024). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. The Lancet, 404(10467), 2077–2093. https://doi.org/10.1016/S0140-6736(24)02317-1/ATTACHMENT/EFD1F5AD-0EA4-474B-A131-0C2B6F00088B/MMC1.PDF

Related topics